Personalized medicine: The future is not what it used to be

Surgery

Volumn 146, Issue 6, 2009, Pages 971-978

  Demeure, Michael J ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COLORECTAL CANCER; GENETIC ANALYSIS; GENOMICS; MEDICAL CARE; MEDICAL LITERATURE; MEDICAL PRACTICE; MEDICAL RESEARCH; PRIORITY JOURNAL; RISK FACTOR;

ADRENAL CORTEX NEOPLASMS; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; SOCIETIES, MEDICAL; SURGICAL PROCEDURES, OPERATIVE; UNITED STATES;

EID: 70549111063     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2009.10.023     Document Type: Article

References (30)

1. You Y.N., Lakhani V.T., and Wells S.A. The role of prophylactic surgery in cancer prevention. World J Surg 31 (2007) 450-464
2. Järvinen H.J., Aarnio M., Mustonen H., Aktan-Collan K., Aaltonen L.A., Peltomäki P., et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118 (2000) 829-834
3. Syngal S., Weeks J.C., Schrag D., Garber J.E., and Kuntz K.M. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 129 (1998) 787-796
4. Olschwang P., Laurent-Puig, Eisinger F., and Millat B. An alternative to prophylactic colectomy for colon cancer prevention in HNPCC syndrome. Gut 54 (2005) 169
5. Ford D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62 (1998) 676-689
6. King M.C., Marks J.H., and Mandell J.B. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (2003) 643-646
7. Brekelmans C.T.M., Seynaeve C., Bartels C.C., Tilanus-Linthorst M.M., Meijers-Heijboer E.J., Crepin C.M., et al. Rotterdam Committee for Medical and Genetic Counseling. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19 (2001) 924-930
8. King M., Wieand S., Hale K., Lee M., Walsh T., Owens K., et al. National Surgical Adjuvant Breast and Bowel Project. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286 (2001) 2251-2256
9. Meijers-Heijboer H., van Geel B., van Putten W.L., Henzen-Logmans S.C., Seynaeve C., Menke-Pluymers M.B., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345 (2001) 159-164
10. Hartman L.C., Sellers T.A., Schaid D.J., Frank T.S., Soderberg C.L., Sitta D.L., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Nat Cancer Inst 93 (2001) 1633-1637
11. Rebbeck T.R., Friebel T., Lynch H.T., Neuhausen S.L., van 't Veer L., Garber J.E., et al. Bilateral prophylactic mastectomy reduces the breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22 (2004) 1055-1062
12. Frost M.H., Schaid D.J., Sellers T.A., Slezak J.M., Arnold P.G., Woods J.E., et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284 (2000) 319-324
13. Heshmati H.M., Gharib H., van Heerden J.A., and Sizemore G.W. Advances and controversies in the diagnosis and management of medullary thyroid cancer. Am J Med 103 (1997) 60-69
14. Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K., Lairmore T.C., et al. Mutations in the RET proto-oncogene are associated with MEN2A and FMTC. Hum Mol Genet 2 (1993) 851-856
15. Mulligan L.M., Kwok J.B., Healey C.S., Elsdon M.J., Eng C., Gardner E., et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 (1993) 458-460
16. Eng C., Clayton D., Schuffenecker I., Lenoir G., Cote G., Gagel R.F., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276 (1996) 1575-1579
17. Wells Jr. S.A., Chi D.D., Toshima K., Dehner L.P., Coffin C.M., Dowton S.B., et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia 2A. Ann Surg 220 (1994) 237-247
18. Quayle F.J., Fialkowski E.A., Benveniste R., and Moley J.F. Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 142 (2007) 800-805
19. Machens A., Braukhoff M., Holzhausen H.-J., Thanh P.N., Lehnert H., and Dralle H. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 90 (2005) 3999-4003
20. Lee S., Nakamura E., Yang H., Wei W., Linggi M.S., Sajan M.P., et al. Neuronal apoptosis linked to EgIN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8 (2005) 155-167
21. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 12 (2005) 245-262
22. Ries L.A.G., Melbert D., Krapcho M., et al. SEER cancer statistics review, 1975-2004 (2007), National Cancer Institute, Bethesda, MD. Available from: URL: http//seer.cancer.gov/csr/1975_2004
23. Xing M. BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocrine Rev 28 (2007) 742-762
24. Mercer K.E., and Pritchard C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653 (2003) 25-40
25. Lee J.H., Lee E.S., and Kim Y.S. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110 (2007) 38-46
26. Lupi C., Giannini R., Ugolini C., Proietti A., Berti P., Minuto M., et al. Association of BRAF V600E mutation with poor clinicopathologic outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92 (2007) 4085-4090
27. Xing M., Westra W.H., Tufano R.P., Cohen Y., Rosenbaum E., Rhoden K.J., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90 (2005) 6373-6379
28. Magnaldo T. SHH (Sonic hedgehog). Atlas Genet Cytogenet Oncol Haematol. February 2002. Available from: URL: http://AtlasGeneticsOncology.org/Genes/SHHID378.html.
29. Hambley T.W., and Hait W.N. Is anticancer drug development heading in the right direction?. Cancer Res 69 (2009) 1259-1261
30. Check Hayden E. Cancer complexity slows quest for cure. Nature 455 (2008) 148